Manila Times Business
MultiValent Biotherapies Launches with $27 Million Series A Financing to Advance Development of Targeted Prostate Cancer Drug Conjugate
- First closing of $27 million Series A financing - - Fundingwill support Phase 1b/2a clinical trial of MVB-101, a prostate-specific membrane antigen x folate receptor alpha (PSMA x FRα) targeted drug conjugate - - Exclusive license to MVB-101, developedby Coherent Biopharma - LOS ALTOS, Calif., June 16, 2026 (GLOBE NEWSWIRE) -- MultiValent Biotherapies, Inc. (MultiValent), a private biotechnology company developing targeted drug conjugate therapies for cancer, announced a $27.425 million first
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →